Zoetis (NYSE:ZTS) Reaches New 52-Week Low – Time to Sell?

Zoetis Inc. (NYSE:ZTS)’s stock price reached a new 52-week low on Tuesday . The stock traded as low as $122.00 and last traded at $126.24, with a volume of 1254446 shares traded. The stock had previously closed at $144.35.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ZTS. UBS Group decreased their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus set a $140.00 price target on shares of Zoetis in a research note on Tuesday. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $191.00.

Zoetis Trading Down 0.6%

The stock has a market capitalization of $53.10 billion, a price-to-earnings ratio of 20.62, a PEG ratio of 2.31 and a beta of 0.90. The company’s 50-day moving average is $145.63 and its 200-day moving average is $153.01. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same period last year, the business earned $1.58 earnings per share. Zoetis’s revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Institutional Investors Weigh In On Zoetis

Institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC grew its holdings in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares in the last quarter. DekaBank Deutsche Girozentrale grew its holdings in shares of Zoetis by 11.3% in the first quarter. DekaBank Deutsche Girozentrale now owns 370,422 shares of the company’s stock valued at $60,174,000 after purchasing an additional 37,544 shares in the last quarter. Flossbach Von Storch SE acquired a new position in shares of Zoetis in the first quarter valued at approximately $292,000. Greenleaf Trust grew its holdings in shares of Zoetis by 16.7% in the first quarter. Greenleaf Trust now owns 9,689 shares of the company’s stock valued at $1,595,000 after purchasing an additional 1,386 shares in the last quarter. Finally, Cornerstone Planning Group LLC grew its holdings in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.